drugset / Trial / NCT00763932

Extension Study of Long-term Safety and Efficacy of Myozyme in Patients With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored Enzyme Replacement Therapy (ERT) Studies

NCT00763932

Phase 2 Completed 7 enrolled Genzyme, a Sanofi Company
NaSingle-groupOpen-labelTreatment

Summary

This extension study was to monitor the long-term safety and efficacy of rhGAA treatment in patients with infantile-onset Pompe disease who were previously treated with rhGAA derived from the Synpac cell line

Timeline

Start
2003-04
Primary completion
2006-06
Completion
2006-07

Drugs

EvaluationDrugModalityDoseRoute
Subject alglucosidase alfa Protein / enzyme biologic 10 mg/kg
Subject alglucosidase alfa Protein / enzyme biologic 20 mg/kg
Subject alglucosidase alfa Protein / enzyme biologic 40 mg/kg